Inovio Pharmaceuticals Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Inovio Pharmaceuticals şirketinin kazançları yıllık ortalama -0.6% oranında azalırken, Biotechs sektörünün kazançları yıllık 19.3% oranında artan oldu. Gelirler yıllık ortalama 9.5% oranında azalan oldu.

Anahtar bilgiler

-0.6%

Kazanç büyüme oranı

17.2%

EPS büyüme oranı

Biotechs Sektör Büyümesi	17.0%
Gelir büyüme oranı	-9.5%
Özkaynak getirisi	-153.5%
Net Marj	-55,491.1%
Son Kazanç Güncellemesi	30 Sep 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Here's Why We're Watching Inovio Pharmaceuticals' (NASDAQ:INO) Cash Burn Situation

Aug 11

Some Analysts Just Cut Their Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Estimates

May 15

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Just Reported And Analysts Have Been Cutting Their Estimates

May 13

Is Inovio Pharmaceuticals (NASDAQ:INO) Using Debt Sensibly?

Oct 23

Inovio reports positive phase 1/2 results for recurrent respiratory papillomatosis drug

Oct 13

Inovio Pharmaceuticals: Long On Promise, Short On Results

Sep 27

Inovio Pharmaceuticals GAAP EPS of -$0.46 misses by $0.15, revenue of $0.78M beats by $0.26M

Aug 09

Inovio Pharmaceuticals: Forget The COVID Pump, And Keep Your Eye On The Oncology Side

Nov 18

Rock star Growth Puts Inovio Pharmaceuticals (NASDAQ:INO) In A Position To Use Debt

Sep 24

Inovio: Simply Cannot Be Ignored

Sep 03

Gelir ve Gider Dağılımı

Inovio Pharmaceuticals nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NasdaqCM:INO Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri
30 Sep 24	0	-113	40
30 Jun 24	1	-122	41
31 Mar 24	1	-125	45
31 Dec 23	1	-135	48
30 Sep 23	1	-165	37
30 Jun 23	10	-168	39
31 Mar 23	10	-241	73
31 Dec 22	10	-280	76
30 Sep 22	11	-332	90
30 Jun 22	2	-355	92
31 Mar 22	2	-328	56
31 Dec 21	2	-304	54
30 Sep 21	7	-221	48
30 Jun 21	6	-142	45
31 Mar 21	6	-188	44
31 Dec 20	7	-166	37
30 Sep 20	2	-180	37
30 Jun 20	3	-222	33
31 Mar 20	3	-123	28
31 Dec 19	4	-119	27
30 Sep 19	6	-115	24
30 Jun 19	7	-117	25
31 Mar 19	32	-94	27
31 Dec 18	30	-97	29
30 Sep 18	37	-86	32
30 Jun 18	37	-95	31
31 Mar 18	33	-97	30
31 Dec 17	42	-88	28
30 Sep 17	42	-93	27
30 Jun 17	52	-80	27
31 Mar 17	38	-89	26
31 Dec 16	35	-74	24
30 Sep 16	33	-65	22
30 Jun 16	44	-39	20
31 Mar 16	44	-27	19
31 Dec 15	41	-29	18
30 Sep 15	37	-19	17
30 Jun 15	15	-31	16
31 Mar 15	13	-36	16
31 Dec 14	10	-36	16
30 Sep 14	10	-44	16
30 Jun 14	17	-68	16
31 Mar 14	14	-68	15
31 Dec 13	13	-66	14

Kaliteli Kazançlar: INO şu anda kârlı değil.

Büyüyen Kar Marjı: INO şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: INO kârlı değildir ve zararlar son 5 yılda yılda 0.6% oranında artmıştır.

Büyüme Hızlandırma: INO 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: INO kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( 16.6% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: INO hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -153.49% ) sahiptir.

Inovio Pharmaceuticals Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Inovio Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 14, 2024

Inovio Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 08, 2024

First quarter 2024 earnings released: US$1.31 loss per share (vs US$1.89 loss in 1Q 2023)

Inovio Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 13, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Inovio Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 06, 2024

Recent updates

Price target decreased by 25% to US$11.83

New major risk - Financial position

Inovio Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 14, 2024

Consensus revenue estimates fall by 16%

Inovio Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $60 million.

Price target decreased by 11% to US$16.75

Here's Why We're Watching Inovio Pharmaceuticals' (NASDAQ:INO) Cash Burn Situation

New minor risk - Profitability

New major risk - Financial position

Inovio Pharmaceuticals, Inc. Receives Advanced Therapy Medicinal Product Certificate from European Medicines Agency for Quality and Non-Clinical Data for Lead Candidate INO-3107

Inovio Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 08, 2024

INOVIO Announces INO-3107 Receives the Innovation Passport Designation Under U.K. Government's Innovative Licensing and Access Pathway

INOVIO Appointsof Steven Egge as Chief Commercial Officer

Consensus revenue estimates fall by 31%

First quarter 2024 earnings released: US$1.31 loss per share (vs US$1.89 loss in 1Q 2023)

Inovio Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 13, 2024

Inovio Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $35.937522 million.

Inovio Pharmaceuticals, Inc., Annual General Meeting, May 21, 2024

New major risk - Share price stability

Full year 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 11% to US$16.88

Inovio Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 06, 2024

Consensus EPS estimates upgraded to US$4.86 loss

Price target increased by 50% to US$2.00

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Inovio Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Inovio Pharmaceuticals, Inc. Receives FDA Feedback That Data from Completed Phase 1/2 Trial of INO-3107

New minor risk - Market cap size

Consensus revenue estimates decrease by 49%, EPS upgraded

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Inovio Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

New major risk - Share price stability

Inovio Pharmaceuticals, Inc.(NasdaqGS:INO) dropped from Russell 2000 Value Index

Consensus revenue estimates fall by 16%

Some Analysts Just Cut Their Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Estimates

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Just Reported And Analysts Have Been Cutting Their Estimates

First quarter 2023 earnings: EPS and revenues miss analyst expectations

INOVIO Presents New Data from A Phase 1/2 Trial of INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis

Price target decreased by 40% to US$1.40

Inovio Pharmaceuticals, Inc. to Report Q4, 2022 Results on Mar 01, 2023

Inovio Pharmaceuticals, Inc. to Report Q4, 2022 Results on Mar 01, 2023

Inovio Reports Positive Phase 1B Results for INO-4201 as an Ebola Booster for rVSV-Zebov (Ervebo®)

Inovio Pharmaceuticals, Inc. Announces Strategic Reorganization and 11% Reduction of Full-Time Employees

Consensus forecasts updated

Price target decreased to US$2.25

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

INOVIO Provides Update on COVID-19 Heterologous Booster Vaccine Candidate, INO-4800

Inovio Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Is Inovio Pharmaceuticals (NASDAQ:INO) Using Debt Sensibly?

INOVIO Reports Positive Interim Phase 1/2 Results for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis

Inovio reports positive phase 1/2 results for recurrent respiratory papillomatosis drug

Inovio Pharmaceuticals: Long On Promise, Short On Results

Board Member exercised options and sold US$5.9k worth of stock

Consensus revenue estimates fall by 43%

Board Member exercised options and sold US$5.9k worth of stock

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Inovio Pharmaceuticals GAAP EPS of -$0.46 misses by $0.15, revenue of $0.78M beats by $0.26M

Inovio Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Consensus forecasts updated

Inovio: After All These Years

INOVIO Announces Survival Results for INO-5401 + INO-9012 in Combination with Libtayo(R) (cemiplimab) in Patients with Newly Diagnosed GBM

Consensus forecasts updated

INOVIO Announces Board Changes

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$9.57

No longer forecast to breakeven

Inovio: Long-Term Biotech To Own With Several Catalysts Expected In 2022

Board Member exercised options and sold US$13k worth of stock